Title: The fluorescence imaging for laparoscopic and laparotomic endometrial sentinel lymph node biopsy (FILLES) trial: Siriraj Gynecologic sentinel Node of endometrial cancer (SiGN-En) study
Abstract:Results: In total, 32 patients were included: endometrioid (n=18), serous (n=5), carcinosarcoma (n=6), and others (n=3).Among them, 25 (78.1%) had stage IVB disease.The most common NAC regimen was pac...Results: In total, 32 patients were included: endometrioid (n=18), serous (n=5), carcinosarcoma (n=6), and others (n=3).Among them, 25 (78.1%) had stage IVB disease.The most common NAC regimen was paclitaxel-carboplatin (n=25, 78.1%), administered with median of 6 cycles.While 26 (81.3%) showed an objective response, 2 (6.3%) progressed despite NAC.At the time of IDS, 23 (71.9%) achieved complete cytoreduction.During 30.5 months of the median followup, there were 23 recurrences and 7 deaths, corresponding to 19 months of median PFS and 46.7% of 3-year OS rate.In multivariate analysis, endometrioid histology was associated with better PFS (hazard ratio [HR]=0.181;p=0.001) and OS (HR=0.112;p=0.029), while complete cytoreduction significantly improved PFS (HR=0.258;p=0.008). Conclusion:We found NAC-IDS is feasible and effective in unresectable, metastatic endometrial cancer.Tumor histology and the possibility of complete cytoreduction would be the primary considerations for NAC-IDS.Read More